Market Overview

AstraZeneca Confirms Exploring Potential Strategic Options With Acerta Pharma

Related AZN
The Best BioPharma Plays Amid Uncertainty From Trump Comments
Here's What Merck's Keytruda News Means For Bristol-Myers
Week In Review: WuXi AppTec Acquires HD Biosciences In China CRO Tieup (Seeking Alpha)

Further to recent speculation, AstraZeneca (NYSE: AZN) confirms that it is exploring potential strategic options with Acerta Pharma BV. There can be no certainty that any transaction will ultimately be entered into, or as to the terms of any transaction.

The Company will make a further announcement if and when appropriate.

Dow Jones first reported a potential deal between the companies on Friday.

AstraZeneca shares closed down $0.22 on Friday, at $33.25.

Posted-In: News M&A Press Releases


Related Articles (AZN)

View Comments and Join the Discussion!